Akero Therapeutics Inc Stock
Akero Therapeutics Inc Stock
Akero Therapeutics Inc gained 0.190% compared to yesterday.
Akero Therapeutics Inc is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
Based on the current price of 18.26 € the target price of 38 € shows a potential of 108.16% for Akero Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akero Therapeutics Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | 0.190% | -6.457% | -15.992% | -55.476% | -16.261% | - | - |
| Ardelyx Inc. | 28.120% | 34.723% | 18.969% | 89.624% | 39.758% | 44.250% | - |
| Evolus Inc | 10.280% | 12.381% | -5.600% | 60.544% | 30.387% | 60.544% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | 7.981% | 17.949% | -67.606% | -17.117% | -98.248% | -99.993% |
Comments
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $39.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at HC Wainwright from $40.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Show more
Ratings data for AKRO provided by MarketBeat